Oceanpine Healthcare Fund

Oceanpine Healthcare Fund is a dedicated healthcare venture fund under Oceanpine Capital, focusing on early-stage companies in healthcare industries with disruptive and innovative technologies. The fund primarily invests in Chinese and U.S. firms with core technologies and proprietary R&D capabilities, aiming to bridge the supply and demand gap exacerbated by limited R&D in China. Their unique 'Dual Market' strategy provides portfolio companies with local resources and guidance, as well as diversification and value realization for investors.

The fund's investment focus includes sectors such as biotechnology, medical devices, innovative drug discovery, genome sequencing, in-vitro diagnostics (IVD), and artificial intelligence applications in the healthcare sector. They primarily target growth-stage companies and selected early-stage companies. Oceanpine Healthcare Fund has established extensive partnerships with academic institutions in the USA, such as the University of Chicago and MD Anderson Cancer Center, to bring research projects from these institutions to China and achieve successful technology transformation.

Since its establishment, the fund has invested in a number of outstanding companies in both China and the USA, including Human Longevity Inc. (Genome Technology), Edigene (Gene editing), and Hua Dao Biotech (CAR-T).